Nearly all surveyed drug sellers (i.e. pharmacists) in the city of Incheon and the provinces of Gyeonggi and Gangwon indicated a decrease, whether small or large, in outpatient prescriptions following the COVID-19 outbreak in South Korea in early 2020. Around half said they had seen decreases of between 11 percent and 30 percent. This trend matches that of most other regions in Korea. Only a small share of four percent of the pharmacists in these city and provinces said there had been no change or even increases in prescriptions. This decrease is attributed to fewer hospital visits in the midst of the COVID-19 crisis.
Changes in hospital outpatient prescriptions since COVID-19 outbreak in Gyeonggi, Incheon, and Gangwon in South Korea in 2020
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Top challenges for pharmaceutical companies during COVID-19 2020
- Basic Statistic Launch disruption on global pharmaceutical market due to coronavirus 2020-2025
- Premium Statistic Changes in outpatient prescriptions in Gwangju and Jeolla South Korea 2020
- Premium Statistic Impact of COVID-19 on revenue of hospitality and retail sector South Korea 2020
- Premium Statistic Impact of COVID-19 on OTC pharmacy sales South Korea 2020
- Premium Statistic Changes in outpatient prescriptions during COVID-19 in Seoul South Korea 2020
- Premium Statistic Merck & Co - expenditure on research and development 2006-2023
- Premium Statistic Changes in outpatient prescriptions in Daejeon and Chungcheong South Korea 2020
- Premium Statistic Adjusted pharmaceutical sales forecast in South Korea 2020, by drug type
- Premium Statistic Changes in outpatient prescriptions in Daegu and Gyeongbuk South Korea 2020
About the region
10
- Basic Statistic Moderna's revenue 2016-2023
- Basic Statistic Moderna total assets 2016-2023
- Basic Statistic Moderna net income 2016-2023
- Basic Statistic R&D expenses of Moderna by type 2023
- Basic Statistic R&D expenses of Moderna 2016-2023
- Basic Statistic Moderna Inc collaboration revenue by related party 2018-2023
- Basic Statistic Projected most valuable R&D projects based on net present value 2023
- Basic Statistic Major COVID-19 vaccines by number of countries using them March 2021
- Basic Statistic COVID-19 vaccines contract size in doses by country and region 2021
- Basic Statistic COVID-19 vaccines by contract size in doses by country and manufacturer 2021
Selected statistics
10
- Basic Statistic GSK's operating profit by division 2006-2021
- Basic Statistic Sanofi's total assets 2007-2023
- Basic Statistic Merck & Co total assets 2009-2023
- Premium Statistic Pfizer's revenues in the U.S. and abroad 2009-2023
- Basic Statistic Merck & Co cash dividends declared 2006-2023
- Premium Statistic Johnson & Johnson's number of employees 2004-2023
- Premium Statistic Sales of Johnson & Johnson worldwide 2011-2023, by segment
- Premium Statistic Sales of Johnson & Johnson 2006-2023 by region
- Premium Statistic AstraZeneca's expenditure on research and development 2006-2023
- Premium Statistic Global pharmaceutical pipeline by therapy area 2013-2017
Other regions
9
- Basic Statistic Amount of top U.S. biotech venture financings 2022
- Basic Statistic Revenue of pharmaceutical markets in Central and Eastern Europe 2021-2022
- Premium Statistic Biotech industry growth rates in Australia compared to worldwide 2016
- Basic Statistic Revenue of leading European pharmaceutical markets 2022
- Premium Statistic Market size of biopharmaceuticals in China 2013-20225
- Premium Statistic COVID-19: impact on the research line of biotech firms in Spain 2020
- Basic Statistic Share of Canadians who would get vaccinated for COVID Jul. 2020 - Mar. 2021
- Premium Statistic Sales revenue Yuhan 2015-2023
- Premium Statistic Distribution of North American in vitro toxicology testing market by technology 2016
Related statistics
10
- Premium Statistic Impact of COVID-19 on pharmacy operations in South Korea 2020
- Premium Statistic Impact of COVID-19 on inbound tourist arrivals South Korea 2020
- Premium Statistic Pharmaceuticals market size South Korea 2012-2022
- Premium Statistic Number of companies in biotech industry in South Korea 2022, by sector
- Premium Statistic R&D investment value in biotech industry in South Korea 2022, by sector
- Premium Statistic Impact of COVID-19 on revenue of airlines and duty-free South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Busan and Gyeongnam South Korea 2020
- Basic Statistic Gender distribution of COVID-19 death cases South Korea 2023
- Basic Statistic Age distribution of COVID-19 death cases South Korea 2023, by age group
- Basic Statistic Age comparison of COVID-19 fatality rate South Korea 2023
Further related statistics
10
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Annual revenue of Sinopharm 2010-2022
- Revenue of Sinopharm 2011-2022, by category
- Annual revenue of Shanghai Pharmaceuticals 2011-2022
- Celgene's revenue and net income 2006-2018
- Key figures on established biotech centers worldwide 2012-2016
- M&A capacities - changes for the global pharma industry 2008-2015
- Total sales of the Richemont Group worldwide 2008-2023
- Operating income of the Industrial and Commercial Bank of China 2012-2022
Further Content: You might find this interesting as well
Statistics
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Annual revenue of Sinopharm 2010-2022
- Revenue of Sinopharm 2011-2022, by category
- Annual revenue of Shanghai Pharmaceuticals 2011-2022
- Celgene's revenue and net income 2006-2018
- Key figures on established biotech centers worldwide 2012-2016
- M&A capacities - changes for the global pharma industry 2008-2015
- Total sales of the Richemont Group worldwide 2008-2023
- Operating income of the Industrial and Commercial Bank of China 2012-2022
IQVIA. (March 31, 2020). Changes in hospital outpatient prescriptions since COVID-19 outbreak in Gyeonggi, Incheon, and Gangwon in South Korea in 2020 [Graph]. In Statista. Retrieved May 09, 2024, from https://www.statista.com/statistics/1120093/south-korea-changes-in-outpatient-prescriptions-gyeonggi-incheon-gangwon/
IQVIA. "Changes in hospital outpatient prescriptions since COVID-19 outbreak in Gyeonggi, Incheon, and Gangwon in South Korea in 2020." Chart. March 31, 2020. Statista. Accessed May 09, 2024. https://www.statista.com/statistics/1120093/south-korea-changes-in-outpatient-prescriptions-gyeonggi-incheon-gangwon/
IQVIA. (2020). Changes in hospital outpatient prescriptions since COVID-19 outbreak in Gyeonggi, Incheon, and Gangwon in South Korea in 2020. Statista. Statista Inc.. Accessed: May 09, 2024. https://www.statista.com/statistics/1120093/south-korea-changes-in-outpatient-prescriptions-gyeonggi-incheon-gangwon/
IQVIA. "Changes in Hospital Outpatient Prescriptions since Covid-19 Outbreak in Gyeonggi, Incheon, and Gangwon in South Korea in 2020." Statista, Statista Inc., 31 Mar 2020, https://www.statista.com/statistics/1120093/south-korea-changes-in-outpatient-prescriptions-gyeonggi-incheon-gangwon/
IQVIA, Changes in hospital outpatient prescriptions since COVID-19 outbreak in Gyeonggi, Incheon, and Gangwon in South Korea in 2020 Statista, https://www.statista.com/statistics/1120093/south-korea-changes-in-outpatient-prescriptions-gyeonggi-incheon-gangwon/ (last visited May 09, 2024)
Changes in hospital outpatient prescriptions since COVID-19 outbreak in Gyeonggi, Incheon, and Gangwon in South Korea in 2020 [Graph], IQVIA, March 31, 2020. [Online]. Available: https://www.statista.com/statistics/1120093/south-korea-changes-in-outpatient-prescriptions-gyeonggi-incheon-gangwon/